Skip to content

Study · Not a test of the peptide alone · 1983

2 results

Multiplicity of receptors for vasoactive intestinal polypeptide (VIP): differential effects of apamin on binding in brain, uterus and liver.

Fahrenkrug J, Gammeltoft S, Staun-Olsen P, Ottesen B, Sjöquist A

Peptides1 Mar 1983Cited by 19 (Europe PMC)

PMID6312430 (opens in a new tab)DOI10.1016/0196-9781(83)90102-x (opens in a new tab)PepBankPUB-06312430
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In rat brain and hog uterus membranes, apamin inhibited the binding of radiolabelled VIP to its receptors, with an affinity 100-1000 times lower than for VIP.

    In plain wordsIn lab tests on rat brain and pig uterus membranes, apamin blocked binding of labelled VIP, but much more weakly than VIP did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseApamin inhibition of 125I-VIP binding in brain and myometrium membranes
    Study

    rat, hogn: not reported in source

    membranes and cells from brain, uterus and liver
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Apamin inhibited the receptor-bound 125I-VIP on membranes from brain or myometrium, although the binding affinity was 100-1000 times lower than for VIP.
    1 context sentence
    Summary · context
    Since vasoactive intestinal polypeptide (VIP) has been proposed as a possible inhibitory neurotransmitter, the effect of apamin on the receptor binding of 125I-VIP was studied using the following assays: (1) isolated synaptosomes from rat cerebral cortex, (2) crude plasma membranes from hog uterine…

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In hog liver membranes and cells, apamin up to 50 mumol/l did not displace radiolabelled VIP from its receptors.

    In plain wordsIn lab tests on pig liver membranes and cells, apamin did not displace labelled VIP, even at high concentration.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeApamin displacement of 125I-VIP binding in liver membranes and cells
    Study

    rat, hogn: not reported in source

    membranes and cells from brain, uterus and liver
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In membranes and cells from liver, apamin was unable to displace receptor-bound 125I-VIP in concentrations up to 50 mumol/l.
    1 context sentence
    Summary · context
    Since vasoactive intestinal polypeptide (VIP) has been proposed as a possible inhibitory neurotransmitter, the effect of apamin on the receptor binding of 125I-VIP was studied using the following assays: (1) isolated synaptosomes from rat cerebral cortex, (2) crude plasma membranes from hog uterine…

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.